- Home
- CDT vs AWH Comparison
CDT vs AWH Comparison
Compare CDT & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- AWH
- Stock Information
- Founded
- CDT 2019
- AWH 1993
- Country
- CDT United States
- AWH United States
- Employees
- CDT N/A
- AWH N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- AWH Medical/Dental Instruments
- Sector
- CDT Health Care
- AWH Health Care
- Exchange
- CDT Nasdaq
- AWH Nasdaq
- Market Cap
- CDT 11.1M
- AWH 10.5M
- IPO Year
- CDT N/A
- AWH N/A
- Fundamental
- Price
- CDT $0.06
- AWH $0.44
- Analyst Decision
- CDT
- AWH Buy
- Analyst Count
- CDT 0
- AWH 2
- Target Price
- CDT N/A
- AWH $4.40
- AVG Volume (30 Days)
- CDT 104.2M
- AWH 93.3K
- Earning Date
- CDT 02-14-2025
- AWH 11-14-2024
- Dividend Yield
- CDT N/A
- AWH N/A
- EPS Growth
- CDT N/A
- AWH N/A
- EPS
- CDT N/A
- AWH N/A
- Revenue
- CDT N/A
- AWH $8,963,000.00
- Revenue This Year
- CDT N/A
- AWH $11.87
- Revenue Next Year
- CDT N/A
- AWH $79.10
- P/E Ratio
- CDT N/A
- AWH N/A
- Revenue Growth
- CDT N/A
- AWH N/A
- 52 Week Low
- CDT $0.05
- AWH $0.38
- 52 Week High
- CDT $3.92
- AWH $5.65
- Technical
- Relative Strength Index (RSI)
- CDT 42.52
- AWH 23.50
- Support Level
- CDT $0.08
- AWH $0.38
- Resistance Level
- CDT $0.18
- AWH $0.58
- Average True Range (ATR)
- CDT 0.02
- AWH 0.07
- MACD
- CDT -0.00
- AWH -0.02
- Stochastic Oscillator
- CDT 0.41
- AWH 15.24
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.